Parabilis Medicines, Inc. filed a Form 8-K on August 25, 2026, reporting the appointment of Craig Tendler as a Class II director effective August 22, 2026, and disclosing the related compensation arrangements.
Key Highlights
- Board expansion: The Board of Directors increased its size from eight to nine members to accommodate the new appointment.
- New director: Craig Tendler was appointed as a Class II director, with his term set to expire at the 2028 annual meeting of stockholders.
- Independence determination: The Board determined that Mr. Tendler is independent under the listing standards of The Nasdaq Stock Market.
- Committee assignment: Mr. Tendler was appointed as a member of the Science & Technology Committee of the Board.
- Stock option grant: Mr. Tendler received an option to purchase 20,294 shares of common stock at an exercise price of $39.36 per share, vesting in thirty-six substantially equal monthly installments over three years.
- Annual cash retainer: Mr. Tendler will receive $40,000 annually for Board service and $7,500 annually for Science & Technology Committee service, each paid quarterly in arrears.
Director Appointment and Compensation Terms at Parabilis Medicines
According to the filing, the Board of Directors of Parabilis Medicines, Inc. (NASDAQ:PBLS) voted on August 22, 2026, to increase the number of directors to nine and to appoint Craig Tendler to fill the newly created vacancy. Mr. Tendler was designated as a Class II director, meaning his term runs until the 2028 annual meeting of stockholders. The Board also determined that Mr. Tendler qualifies as an independent director under Nasdaq listing standards, and assigned him to the Science & Technology Committee.
In accordance with the company's compensation program for non-employee directors, the filing discloses that Mr. Tendler received a stock option to purchase 20,294 shares of common stock at an exercise price of $39.36 per share. The filing states that the option will vest in thirty-six substantially equal monthly installments over three years from the date of grant, and that "all vesting will cease if Mr. Tendler ceases to serve on the Board." In addition, Mr. Tendler will receive an annual cash retainer of $40,000 for Board service and $7,500 for service on the Science & Technology Committee, each to be paid quarterly in arrears and pro-rated based on actual days served during each calendar quarter.
The filing further states that the company entered into an indemnification agreement with Mr. Tendler in the same form as those previously entered into with its other directors. The filing specifies that there are no arrangements or understandings between Mr. Tendler and any other person that led to his selection, no family relationships with other directors or executive officers, and no transactions requiring disclosure under Item 404(a) of Regulation S-K. Parabilis also issued a press release on August 25, 2026, announcing the appointment, furnished as Exhibit 99.1 to the filing.
What Was Disclosed
Parabilis Medicines reported the expansion of its Board to nine members, the appointment of Craig Tendler as an independent Class II director and Science & Technology Committee member, and the associated stock option grant, annual cash retainers, and indemnification agreement.



Please wait processing your request...